Key result
Continuous use of beta-blockers was associated with a significantly lower risk of new heart failure events in breast cancer patients receiving chemotherapy (HR 0.2; 95% CI 0.1-0.5; P=0.003).
Why the study?
Does continuous incidental use of beta-blockers reduce incident heart failure admissions in patients with breast cancer and normal ejection fraction receiving trastuzumab and anthracycline therapy?
Population
318 propensity-matched patients with breast cancer and normal baseline ejection fraction receiving…
Comparison
Continuous incidental use of beta-blocker agents… vs No continuous beta-blocker use during cancer…
Design
Cohort
Follow-up
median 3.2±2.0 years
Authors
Loading...
Should not yet change practice in breast cancer patients on cardiotoxic therapy; leaves open whether beta-blockers prevent incident heart failure.
Cohort (n=318)
No
Does continuous incidental use of beta-blockers reduce incident heart failure admissions in patients with breast cancer and normal ejection fraction receiving trastuzumab and anthracycline therapy?
Effect estimate: HR 0.2 (95% CI 0.1-0.5)
p-value: p=0.003
Incidental continuous use of beta-blockers is associated with a markedly lower risk of incident heart failure in breast cancer patients undergoing cardiotoxic chemotherapy with trastuzumab and anthracyclines.
Seicean et al. (2013) conducted a cohort in Breast cancer undergoing chemotherapy (n=318). Continuous use of β-blocker agents vs. No continuous β-blocker use was evaluated on New heart failure events (HR 0.2, 95% CI 0.1-0.5, p=0.003). Continuous use of beta-blockers was associated with a significantly lower risk of new heart failure events in breast cancer patients receiving chemotherapy (HR 0.2; 95% CI 0.1-0.5; P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: